Agenus Inc. (AGEN, Financial), a clinical-stage biotech firm, experienced a significant stock drop of 5.08%, trading at $2.90 per share with a volume of 204,158 shares. The company's recent financials show revenue of $25.11 million, a net loss of $66.39 million, and earnings per share of -$3.08. Despite these figures, 20% of analysts recommend buying, while 80% suggest holding, with no sell recommendations.
In the biotech sector, which rose 0.87%, other stocks like Tonix Pharmaceuticals and Sagimet Biosciences saw notable gains. Agenus focuses on therapies to activate the immune system against cancer and infections, with key candidates being botensilimab (AGEN1811) and balstilimab.
